External announcement
GEXVal Participates in “JAPAN HEALTHCARE VENTURE SUMMIT 2022”New!!

GEXVal Inc. September 30, 2022 GEXVal will participate in JAPAN HEALTHCARE VENTURE SUMMIT 2022, which is an As […]

Read more
R&D
GEXVal Interviewed at World Fragile X Day

GEXVal Inc.August 10, 2022 GEXVal announced today that Dr. Lili Mao, Director of the Clinical Development Unit […]

Read more
R&D
Phase I Clinical Trial of GXV-001 Initiated in Australia

GEXVal Inc. is pleased to announce that we have officially initiated phase I clinical trial of its drug candid […]

Read more
External announcement
GEXVal Participates in “Venture Innovation Pavilion2022”

GEXVal Inc. July 7, 2022  GEXVal will participate in the Venture Innovation Pavilion at PharmaLab EXPO JAPAN 2 […]

Read more
R&D
HREC Approval of the Initiation of Phase 1 Study of GXV-001 in Australia

GEXVal Inc.June 10, 2022 GEXVal Inc. has invited experienced doctors and specialists from Japan, Australia, Sw […]

Read more